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The estrogen receptor and glucocorticoid receptor are members of the nuclear receptor
superfamily that can signal using both non-genomic and genomic transcriptional modes.
Though genomic modes of signaling have been well characterized and several behav-
iors attributed to this signaling mechanism, the physiological significance of non-genomic
modes of signaling has not been well understood. This has partly been due to the contro-
versy regarding the identity of the membrane ER (mER) or membrane GR (mGR) that may
mediate rapid, non-genomic signaling and the downstream signaling cascades that may
result as a consequence of steroid ligands binding the mER or the mGR. Both estrogens
and glucocorticoids exert a number of actions on the hypothalamus, including feedback.
This review focuses on the various candidates for the mER or mGR in the hypothalamus
and the contribution of non-genomic signaling to classical hypothalamically driven behaviors
and changes in neuronal morphology. It also attempts to categorize some of the possible
functions of non-genomic signaling at both the cellular level and at the organismal level that
are relevant for behavior, including some behaviors that are regulated by both estrogens
and glucocorticoids in a potentially synergistic manner. Lastly, it attempts to show that
steroid signaling via non-genomic modes may provide the organism with rapid behavioral
responses to stimuli.
Keywords: hypothalamus, spine density, membrane-initiated signaling, GPCR, estrogen receptor variants, aggres-
sion, lordosis, glucocorticoid receptor
GENOMIC AND NON-GENOMIC SIGNALING BY NUCLEAR
RECEPTORS
Nuclear receptor ligands such as estrogen and glucocorticoids sig-
nal via both non-genomic and genomic pathways within cells. The
genomic or transcriptional pathway is the best elucidated primar-
ily due to the well-characterized nature of the estrogen receptor
(ER)α and β and the glucocorticoid receptor (GR), all of which
are members of the nuclear receptor superfamily. Once bound to
their cognate ligands, these receptors act as ligand-activated tran-
scription factors in the nucleus by binding to specific enhancer
elements such as the estrogen response element (ERE) (1) and
glucocorticoid response element (GRE) (2) in the promoters of
genes. Both receptors have a modular structure, with a conserved
DNA-binding domain, multiple transactivation domains, and a
C-terminal ligand-binding domain (3, 4).
On the other hand, non-genomic signaling, first described
by Szego and Davis in 1967, as the rapid increase in cAMP
in the uterus occurred within 15 min of 17β-estradiol (17β-E)
administration to ovariectomized mice (5). In the central ner-
vous system (CNS), 17β-E was shown to rapidly depolarize pro-
opiomelanocortin (POMC) hypothalamic neurons via Akt or pro-
tein kinase (PK) B, extracellular regulated kinase (ERK/MAPK),
PKA, and PKC pathways (6, 7). In other tissues such as rat hip-
pocampal neurons, phospho-cAMP response element binding
protein (pCREB) increased within 1 h of 17β-E addition and this
increase was blocked by inhibitors to both calmodulin kinase II
(CamKII) and ERK pathways (8). In the case of corticosterone-
mediated rapid actions, treatment of neurons with dexametha-
sone, a synthetic glucocorticoid, rapidly induced the nuclear local-
ization of the GR (9, 10), an effect potentiated by the inhibition
of p38MAPK (11). Extracts from rat hippocampal synaptoneu-
rosomes showed a reduction in Akt and ERK phosphorylation
within 30 min in response to pharmacological inhibition of the
GR by RU-486 (12), suggesting that the classical nuclear recep-
tor was required for non-genomic signaling in the hippocampus.
Apart from kinase activation, dexamethasone-mediated negative
feedback at the corticotropin releasing hormone (CRH) neuron
was also rapid, consisting of suppression of the excitatory drive
to the CRH neuron, mediated by endocannabinoids acting as a
retrograde messenger to the presynaptic glutamatergic neuron
(13), an effect mimicked with a membrane-limited dexametha-
sone conjugated to bovine serum albumin (Dex-BSA) (13). Hence,
non-genomic signaling by steroid hormones is extra-nuclear sig-
naling that is initiated by the endogenous ligand within minutes, in
contrast to the hours required to detect transcriptionally regulated
proteins.
Central to this concept of non-genomic signaling that is typ-
ically demonstrated by the use of membrane-limited conjugates
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(14), is the idea of a receptor that initiates such signaling from the
plasma membrane. However, with the exception of the membrane
progesterone receptors (mPRs) that belong to the progestin and
adipoQ receptor (PAQR) family, the identity of the membrane
ER (mER) and membrane GR (mGR) has remained elusive (15).
This review aims to describe the current candidates for the mER
and the mGR that mediate rapid non-genomic signaling from the
plasma cell membrane as well as focus on rapid actions that are
relevant for hypothalamically driven behaviors that are dependent
on estrogens but that have a glucocorticoid-regulated component.
We concentrate on the hypothalamus since this is a classically
steroid-responsive area of the brain and is critical for several
estrogen-dependent behaviors (16). For more general reviews on
rapid actions of estrogens and glucocorticoids in the CNS, includ-
ing tools that are typically used to elucidate membrane-initiated
non-genomic effects, the reader is referred to (7, 14, 17–19).
THE MEMBRANE ER AND GR
In the CNS, both 3H-labeled 17β-E (20) and a 125I-labeled
membrane-impermeant conjugate where 17β-E is attached to
bovine serum albumin (E2-BSA) (21) showed relatively high affin-
ity binding to rat plasma membranes, suggesting the presence of
a mER. What is a good definition for a mER or mGR? Previously,
Micevych et al. (22) have suggested that ICI 182,780 antagonism,
stereospecific 17β-E binding and sequence homology to the ERα
and ERβ should be considered pre-requisites for a protein to be
termed a mER. We propose, given the off-target effects of ICI
182,780 (23) that the definition of the mER or mGR be mod-
ified slightly to consider proteins capable of specific binding to
17β-E or to dexamethasone (in the case of the mGR), presence
at/near the plasma membrane and signaling from the membrane.
It should be noted that this definition would exclude the binding of
proteins to 17α-E, an estrogen often used in studies of as an inac-
tive isomer of 17β-estradiol, but that recently has been shown to
increase neurogenesis and to mediate neuroprotection (24). Most
studies described below show evidence of the candidate mER at
the plasma membrane and its ability to rapidly within minutes
modulate rapid signaling pathways such as kinase regulation or
calcium flux. A few studies also demonstrate the regulation of the
candidate ER at the membrane.
ERα AS THE mER
As we will focus on outputs dependent on the hypothalamus in
this review, we will initially discuss the nuclear classical ERα as a
candidate mER because (a) this is the most abundant ER isoform
in the medial preoptic area (mPOA), ventromedial hypothalamus
(VMH), and arcuate nucleus (ARH) (25–27) and (b) loss of ERα
in the hypothalamus abrogated hypothalamically driven lordosis
behavior in females (28) and aggressive behavior in males (29).
A number of studies using 17β-E binding, electron microscopy,
immunocytochemistry, and western blotting have examined the
idea that a small percentage (3–5%) of the total pool of the classi-
cal ERα is present on the plasma membrane (30). Consistent with
this idea, immunocytochemistry using minimal fixation in both
the breast cancer MCF-7 cell line (31) and anterior pituitary GH3
cell line (32), revealed ERα at the membrane in caveolae in some,
but not all cells. MCF-7 cells with ERα at the plasma membrane
showed increased phospho-ERK (pERK) within 10 min of appli-
cation of either 17β-E or a membrane-limited E2-peroxidase
conjugate (33). In the CNS, ERα was localized to the dendrites
and axon terminals in the guinea pig hypothalamus (34), while
ERα was detected in axon terminals, dendritic spines, as well as in
astrocytes in the CA1 using immuno-electron microscopy in the
proestrous female rat (35). In the dorsal CA1 from the female rat,
ERα was present in synaptic vesicles in the axon of some GABAer-
gic basket cells; 17β-E moved these ERα-containing vesicles toward
synapses within 24 h (36). In addition, some proportion of this
extra-nuclear ERα at synaptosomes and vesicles was phosphory-
lated though the function of phosphorylation in localization of
the ERα remains unknown (37). In hypothalamic neurons and
astrocytes obtained from both male and female rats, a full-length
66 kDa form of the ERα and a 52 kDa variant has been detected
using surface biotinylation and immunocytochemistry (38, 39).
These studies demonstrate that the nuclear ERα is present at the
plasma membrane in many cell types, including the hypothalamus.
TARGETING OF ERα TO THE PLASMAMEMBRANE
Though hydropathicity analysis shows that ERαmay have a poten-
tial trans-membrane domain (38), the idea that ERα requires a
membrane protein to tether it to the plasma membrane has been
cemented primarily by the discovery of caveolin proteins that can
anchor the ERα in lipid rafts and caveolae. Caveolin proteins are
highly conserved structural proteins that are necessary and suffi-
cient for the existence of caveolae, a subset of lipid rafts (40) that
comprise a restricted compartment for signaling molecules asso-
ciated with the plasma membrane. Initially, ERα was reported to
interact with caveolin 1 (Cav-1) in MCF-7 and vascular smooth
muscle cells (VSMC) (41). The caveolins in turn act as adaptor
proteins to couple ERα selectively to either other proteins such as
the metabotrophic glutamate receptors (mGluR) or to processes
such as palmitoylation. In the hippocampus of the female rat, Cav-
1 interacted with mGluR1a so that 17β-E activated downstream
Gαq and ERK signaling. This, in turn, increased pCREB activa-
tion within 5 min of 17β-E application (42). Hence, inhibitors to
phospholipase C (PLC) and ERK and mGluR1a as well as a dom-
inant negative Cav-1 mutant decreased pCREB activation (42).
On the other hand, Cav-3 tethered ERα in hippocampal neu-
rons to mGluR2/3; this pathway activated Gαi signaling, leading
to the inhibition of PKA and the subsequent downregulation of
pCREB (42). Hence, the type of caveolin dictated the final diver-
gent pCREB response though the physiological conditions wherein
ERα may bind to Cav-1 versus Cav-3 are unknown. In hypothal-
amic astrocytes, the coupling of ERα to mGluR1a resulted in an
increase of calcium within 2 min of 17β-E application; this was
blocked both by the ERα and ERβ antagonist, ICI 182,780 and
by the mGluR1a antagonist LY 367385 (43). In striatal neurons,
Cav-1 facilitated the tethering of ERα to mGluR5 and subsequent
Gαq signaling (44). Hence, caveolins may not only tether ERs into
caveolae in the plasma membrane in different cell types but also
subserve tissue-specific signaling to specific Gα subunits by co-
opting different mGluR partners. The coupling of ERα to mGluRs
may allow downstream signaling to be potentiated by rendering it
sensitive to two ligands, i.e., 17β-E for the ER and glutamate for
the mGluR. This is supported by the data that in hypothalamic
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astrocytes, glutamate, and 17β-E combined elicited greater Ca+2
increases than either ligand alone (43).
In addition to the role that mGluRs play in linking ERα to Gα
proteins, ERα can also directly bind Gα subunits. 17β-E inhibited
cAMP production within 5 min of addition to GT1–7 immortal-
ized GnRH neurons via ERα that is physically tethered to Gαi3 (45)
protein that can be detected in co-immunoprecipitation experi-
ments. Interestingly, addition of 17β-E decreased the amount of
membrane-associated Gαi3 and this decrease was blocked by the
ER antagonist ICI 182,780 suggesting control of the signaling cas-
cade by the ligand, similar to classical G-protein coupled receptors
(GPCRs) (45). Though ERα has been demonstrated to tether to
Gαi in the caveolae of endothelial cells to increase the activity of
nitric oxide synthase (46), this mode of regulation of nitric oxide
synthase by 17β-E has not been shown in the CNS.
Apart from serving as adaptors, the binding of caveolins to the
ER also increases palmitoylation of the ER, a process by which
palmitate, a C16 fatty acid is added to an internal cysteine via a
thioester bond. In the human ERα, a canonical palmitoylation site
exists at the cysteine amino acid residue at position 447 (C447); the
corresponding site in the mouse ERα is the C451 (31). Mutant ERα
where the C447 site was mutated to alanine (C447A) did not bind
Cav-1, was not localized at the membrane in HeLa cells and showed
decreased pERK activation in response to a 10-min application of
17β-E (47). Additionally, when a non-classical palmitoylation site,
S522, in the ERα was mutated, localization at the plasma mem-
brane and Cav-1 binding to ERα was decreased (48) in Chinese
hamster ovary (CHO) cells. This mutant also decreased the ability
of 17β-E to increase pCREB in hippocampal neurons from the
female rat (42). Other binding partners for the ERα also lead to
increases in palmitoylation and subsequent membrane localiza-
tion. For example, the amino acid residue cysteine at position 451
of the mouse ERα also binds the heat-shock protein 27 (hsp27),
which increased the rate of palmitoylation at this site. There-
fore, siRNA to hsp27 decreased palmitoylation with subsequent
decrease of ERα at the plasma membrane and decreased phospho-
Akt (pAkt) normally induced by a 10 min application of 17β-E
(49). The C-terminal of mouse ERα (Leu512–514) is important
in ERα dimerization at the plasma membrane; mutation of these
residues decreased pAkt and cAMP generation within 5 min of
17β-E addition and decreased the activation of both Gαs and Gαq
subunits in the CHO cell line (50) (Figure 1). In the CNS, it is
unknown if the ERα at the membrane exists as dimers and if
these dimers use caveolin proteins as adaptors. It is also unclear
if caveolin binding to the ERα precedes greater palmitoylation
since ERα mutations that destroy the interaction with caveolin
also destroy palmitoylation. Recently, E2-BSA has been shown to
transcriptionally upregulate Cav-1 via a PI3K and ERK pathway
within 12 h in endothelial cells (51). Hence, 17β-E may increase
non-genomic signaling both by increasing the palmitoylation of
ERα within rapid time frames and within longer time frames via
the transcriptional upregulation of Cav-1.
REGULATION OF ERα AT THE MEMBRANE BY 17β-E
Similar to the tissue specificity shown by ERα-mediated rapid,
non-genomic signaling, ERα at the membrane is also regulated
by 17β-E in both temporal and tissue-specific manner. In hypo-
thalamic astrocytes (38) and neurons (39) and in a hypothalamic
cell line, mHypoE-38 (52), 17β-E increased the amount of both
the 52 and 66 kDa mER in the cell membrane within 30 min. This
increase of mERα at the plasma membrane can be blocked by ICI
182,780 and the mGluR1a antagonist LY 367385 but does not occur
with E2-BSA, suggesting that this is an internal, non-membrane-
initiated rapid effect that is dependent on the mGluR1a receptor.
In contrast, in MCF-7 cells, 17β-E decreased Cav-1 within 8 h, thus
decreasing the amount of ERα at the membrane. Similarly, 17β-E
ERα 
H AF-2 AF-1 DBD 
185 251 355 595 
H-184 
MC-20 
C1335 
451 522 509 
Gαi 
interaction 
Antibodies: 
1 
AF-1  DBD H AF-2 
421 486 528 777 1 
Coregulator binding Dimerization 
NLS-2 NLS-1 
HSP90 
Coregulator binding 
M-20 
GRα 
BuGR Antibodies: 
FIGURE 1 | Domain structure of the ERα and the GRα. ERα and GRα are
classical intracellular nuclear receptors but may also be present on the plasma
membrane. Both receptors have a N-terminal AF-1 domain, a central DNA
binding domain, a hinge domain (H), and a C-terminal AF-2 domain, required to
bind ligand. ERα: the antibodies most commonly used to detect ERα are the
H184 (Santa Cruz Biotechnology, TX, USA) antibody raised to the N-terminal
domain and the MC-20 (Santa Cruz Biotechnology, TX, USA) and C1335
(Upstate Biotechnology, NY, USA) raised to the C-terminal domain. In addition,
the sites that may tether the ERα to the plasma membrane are marked. These
are residues required for caveolin or Gαi binding or residues that are
palmitoylated or required for dimerization at the membrane. GRα: the
antibodies most commonly used to detect GRα are the BuGR antibody
(Abcam Inc., MA, USA) and the M-20 (Santa Cruz Biotechnology, TX, USA)
antibody, directed to the N-terminal domain. The NLS refers to the nuclear
localization signal since nuclear localization of this receptor can occur rapidly
and is a non-genomic effect.
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treatment of hippocampal slices from female rats removed ERα
from the synaptosomal plasma membrane by depalmitoylation
within 20 min (37). In CHO cells, palmitate incorporation into
ERα and association with Cav-1 decreased within 60 min of 17β-E
administration, suggesting that ERα at the plasma membrane was
lowered, consistent with this idea, ERK activation also decreased
(47). Decreasing ERα at the membrane in these cells may allow
for a decrease in non-genomic signaling and may mark a shift
toward genomic transcription. In contrast, in the VSMC, 17β-E
increased both Cav-1 and Cav-2 and increased ERα localization
at the plasma membrane (41). Such increased ERα localization in
response to the endogenous ligand may be a mechanism to sustain
non-genomic signaling in some cell types.
Similar to other trans-membrane GPCRs, which may undergo
desensitization via internalization in a G-protein receptor kinase
2 (GRK2)-β-arrestin-dependent manner (18), 17β-E application
to cortical neuronal cultures rapidly induced GRK2 phosphory-
lation within 5 min and β-arrestin1 and c-Src recruitment to the
ERαwithin 60 min. Predictably, since β-arrestin1 tagging of trans-
membrane GPCRs provides a scaffold for c-Src attachment and
subsequent ERK activation (53), siRNA to β-arrestin1 abrogated
the 17β-E induction of pERK in these neurons (54). Though the
exact partners of the ERα in this internalized signalosome are
unknown, ERα internalization is initiated from the membrane
since E2-BSA also promotes internalization (54). Internalization
of the ERα has also been tested more directly by using a surface
biotinylation technique followed by stripping the surface biotin
with glutathione after 17β-E addition to cells. Hence, the con-
tinued presence of biotin in this preparation would argue that
the receptor was internalized and protected against glutathione
action. In hypothalamic neurons, addition of 17β-E caused inter-
nalization of both the 52 and 66 kDa forms within 30 min, with
internalization of the 52 kDa form persisting for 2 h (54), demon-
strating that recycling and internalization of the classical ERα as
well as the 52 kDa variant occurs in a rapid time frame. An unre-
solved issue is the rapid decrease in total ERα protein and mRNA
in the hypothalamus on 17β-E application that has been shown
by several investigators (55, 56). However, it is difficult to rec-
oncile this with the increase in plasma mERα that is seen in the
hypothalamic primary neuronal and astrocytic cultures (38, 39)
and in the hypothalamic cell line mHypoE-38 (52) unless ERα
from other non-membrane locations decrease to a large extent;
this could be a parameter to be investigated in future studies. This
could also be due to the recent studies that show an increase ERα at
the plasma membrane being carried out in primary cultures versus
hypothalamic tissue that retain neuronal connectivity in the older
studies.
DEPENDENCE OF RAPID SIGNALING ON ERα AND ERβ
In addition to direct demonstration of the ERα either at the
membrane or tethering to an intrinsic membrane protein, the ER
dependence of kinase activation has also been investigated. Sev-
eral studies, described in this review, have used the ERα and ERβ
antagonist ICI 182,780 to antagonize a rapid signaling pathway or
a genetic approach that deletes either ERα or ERβ specifically in
the whole animal. The availability of ERα and ERβ knockout ani-
mals, i.e., ERαKO and ERβKO, has been useful to understand the
ER dependence of 17β-E-mediated non-genomic signaling in vivo,
particularly in light of an absence of a specific antibody to the ERβ
(57). In wild-type female mice, subcutaneous administration of
17β-E caused the activation of CREB and ERK within an hour,
as measured by immunohistochemistry for the phosphorylated
forms of these molecules. When either ERα or ERβ or both were
deleted, a complex brain nuclei-specific and isoform-specific ER
dependence was revealed, which may in part be due to the tissue
distribution of the ER isoforms in the brain (Table 1 below) (58).
For example, in the ventrolateral VMH (vl-VMH), the loss of ERα
results in the reduction of pCREB on 17β-E administration and
this could be because the predominant ER isoform is the ERα and
it is possible that the loss of ERα cannot be compensated by smaller
amounts of ERβ (58). The use of ERαKO, ERβKO, and ERαβKO
mice in this study showed that ERα is hence both necessary and
sufficient for the induction of pCREB. In the mPOA, 17β-E could
induce pCREB via either ERα or ERβ but required both ERα and
ERβ to act in conjunction in order to induce pERK (58), demon-
strating that ER isoforms can regulate rapid signaling differentially
in the same tissue. The regulation in male mice is unknown and is
under investigation in our laboratory.
ERα VARIANTS
In both hypothalamic neurons and astrocytes (38), a variant
52 kDa ERα (ERα-52), detected with a C-terminal antibody that
also detects the full-length 66 kDa, was expressed in much higher
amounts than the ERα-66 kDa form. Based on RT-PCR analysis
using flanking primers to this exon in the mouse hypothalamic
cell line mHypoE-38, this is believed to be an ERα that lacks
exon 4 (ERα∆4) (52). In astrocytes, only the 66 kDa form is
thought to be interact with mGluR1 (43) and the interaction, sig-
naling properties, and function, if unique, of the 52 kDa variant
remain unknown. A 36 kDa variant lacking the AF-1 and AF-2
domains with a unique C-terminus was detected in human breast
Table 1 | Comparison of CREB and ERK between wild-type (WT), ERα
knockout (ERαKO), ERβ knockout (ERβKO), and double ERα ERβ
knockout (ERαβKO) female mouse brain.
Genotype vlVMH mPOA Medial septum
pCREB pERK pCREB pERK pCREB pERK
WT ++ NR ++ ++ ++ NR
ERαKO − NR ++ − ++ NR
ERβKO ++ NR ++ − − NR
ERαβKO − NR − − − NR
pCREB and pERK in 17β-E injected mice was quantitated by immunohistochem-
istry and compared to the levels of pCREB and pERK present in mice injected
with the vehicle, in the ventrolateral VMH (vl-VMH), the medial preoptic area
(mPOA) and the medial septum in female ovariectomized mice injected with
10µg 17β-E and sacrificed an hour after injection. In WT mice, 17β-E increased
pCREB in the vl-VMH and pERK and pCREB in the mPOA. ER isoform dependence
varies according to the output (pCREB or pERK) measured and the nuclei. ++:
upregulation compared to vehicle-treated mice. −: no upregulation compared to
vehicle-treated mice. NR=data not recorded. Data are from Ref. (58).
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cancer cells, coded for by a unique promoter located in intron
1 of the Esr1gene (59) and can be detected by a specific anti-
body. ERα-36 was localized to the plasma membrane, mediated
rapid ERK signaling, and is induced by the selective activation
of the GPR30 (discussed in Section “GPR30”) by the agonist, G-
1 (60). Importantly, this GPR30-selective activator, G-1, has also
been demonstrated to bind and activate ERα-36 (60), suggest-
ing that some of the responses attributed to the GPR30 might
be via ERα-36. A 46 kDa variant observed in endothelial cells is
also localized to the plasma membrane (61) and is composed of
a splice variant missing the first 173 amino acids of ERα-66 (62).
ERα-46 cannot be detected with an N-terminus antibody raised
to ERα-66 such as H-184 (Figure 1), but should be identifiable
with a C-terminus ERα antibody. A novel ER is the ER-X, an ER
of 63 kDa that is expressed in the neocortex in the caveolae mem-
brane fraction, can be identified with ERα and ERβ antibodies
and is present in the ERα knockout animal (63). This ER, whose
structure remains unidentified, mediated ERK signaling by both
17α-estradiol and 17β-estradiol and would not meet the criteria
for a mER, based on our previous definition. The function and
expression pattern of the ER-X is unknown though it was upreg-
ulated after ischemic injury (63) in the adult. If it is not present in
the adult hypothalamus, it is unlikely to be a receptor that medi-
ates normal behavior that is dependent on the hypothalamus (63).
So far, neither ERα-36 nor ERα-46 has been demonstrated in the
CNS, though it is possible that some antibodies directed toward
the DNA-binding domain or, in the case of the 46 kDa variant, the
C-terminal domain of the full-length 66 kDa ERα such as MC-20
or C1335 (Figure 1) may detect these forms in studies that use
solely immunocytochemistry.
Gα-COUPLED mERs
The idea that the mER is a Gαq-coupled receptor has been explored
in the POMC neuron in the ARH, primarily by the laboratories
of Kelly and Ronnekliev (7, 64, 65). In POMC neurons, 17β-E
and E2-BSA uncoupled the inhibitory µ-opioid receptor from
the G-protein coupled inward rectifying K+ (GIRK) channel, in a
PLC-, PKC-, and PKA-dependent manner (66, 67), thus decreas-
ing hyperpolarization of these neurons and increasing neuronal
excitability. Pharmacological characterization revealed that a Gαq
receptor upregulated PLC and calcium release, which in turn acti-
vated PKC and PKA. Subsequent PKA phosphorylation of the
GIRK channel uncoupled the µ-opioid receptor (7, 68) from
GIRK. Though this response was specific for 17β-E versus 17α-
E and was blocked by the ERα and ERβ antagonist ICI 182,780, it
also occurred in ERαKO, ERβKO, and GPR30 KO mice (69), sug-
gesting that a novel mER is coupled to Gαq. This signaling pathway
can be activated by a selective ligand, STX, which does not bind
ERα, ERβ, or GPR30. Both STX and 17β-E also reduced post-
ovariectomy weight gain, suggesting that this novel Gαq-coupled
mER is important in energy homeostasis. Leptin receptors on
POMC neurons caused depolarization rapidly via the JAK/STAT
and PI3K pathways that open calcium-dependent TRPC channels
(70); 17β-E signaling may synergize with leptin action by increas-
ing calcium rapidly in these neurons via this Gαq-mER. Several
reviews (7, 68, 69, 71–74) detail the studies on this STX-activated
receptor.
GPR30
The GPR30, also known as GPER1, is a former orphan GPCR
that was shown to bind 17β-E and increase cAMP in breast can-
cer SKBR3 cells via an increase in adenylyl cyclase activity (75).
In the rat hypothalamus, GPR30 expression is particularly high
in the PVN and SON (76) with low expression in the VMH. Cell
fractionation and immunocytochemistry revealed GPR30 to be
localized at the plasma membrane in both the SKBR3 (GPR30+,
ERα−, ERβ−) and MDA-MB-231 (GPR30−, ERα−, ERβ+; GPR30
overexpression) breast cancer cell lines (77). Though GPR30 was
not detected at the plasma membrane using surface biotinylation
in hypothalamic astrocytes (38), GPR30 was localized to the post-
synaptic density in the hippocampus and associates with PSD-95
through its C-terminal tail (78). This association with PSD-95
can localize GPR30 to the plasma membrane, independent of
17β-E. Immuno-electron microscopy analysis of rat hippocampi
also revealed membrane localization with no intracellular staining
(79). However, it can be detected intracellularly in normal mam-
mary gland epithelial cells (80) and colocalized with a marker of
the Golgi apparatus in primary cultures of the hippocampus (81).
Also, overexpressed GPR30 in COS7 cells exhibits localization at
the endoplasmic reticulum and the Golgi (82), suggesting that cell
type can determine localization. In addition, HeLa cells transfected
with FLAG-GPR30 show mostly staining at the membrane while
cells transfected with GFP-GPR30 show staining mainly in the
endoplasmic reticulum [(79) #6908], suggesting that inclusion of
molecular tags may interfere with proper intracellular trafficking,
possibly confounding the interpretation of experiments relying on
ectopic expression of GPR30.
Studies describing the regulation of internalization of GPR30
have also yielded conflicting results. When FLAG-GPR30 was
ectopically expressed in HeLa cells, receptor endocytosis was ligand
dependent and internalized GPR30 occupied a diffuse cytoplasmic
localization consistent with classical receptor recycling or protea-
somal degradation pathways (79). In human embryonic kidney
(HEK)-293 cells, GPR30 internalization was not only ligand-
dependent but also occurs constitutively (83). While most GPCRs
are either recycled to the plasma membrane via endosomes or
degraded in lysosomes to limit excessive signaling, GPR30 rapidly
accumulates in the perinuclear compartment via clathrin-coated
vesicles (83). It is thought that this Rab 11-dependent accumu-
lation is in the trans-Golgi network and degradation occurs via
an ubiquitin-proteasome-mediated pathway, unlike the endoso-
mal degradation or recycling to the surface that is typical for
other GPCRs (83). Since this pathway for internalization and
degradation is rapid and constitutive, Cheng et al. propose this
as the reason for the difficulty in detecting GPR30 at the plasma
membrane in some cell lines (83).
GPR30 can signal via both the Gαs and the Gβγ subunits that
are associated with the receptor upon activation. The Gβγ sub-
unit transactivated the EGFR receptor leading to downstream
activation ERK protein, while simultaneous activation of the Gαs
subunit by 17β-E inactivated ERK signaling through activation
of adenylyl cyclase and PKA, thus limiting cAMP signaling to
a short time frame (23). Furthermore, although GPR30 protein
was readily detectable in both the microsomal and plasma mem-
brane subcellular fractions of breast cancer cell lines, only GPR30
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in the plasma membrane fraction bound ligand and activated
G-protein signaling, suggesting that only membrane-associated
GPR30 protein is functional (77). However, GPR30 activation
in COS7 cells initiated intracellular calcium mobilization and
nuclear accumulation of PIP3 via EGFR transactivation (82) via a
non-membrane-initiated signaling mechanism since calcium flux
was not replicated by membrane restricted estradiol derivatives
(84). These discrepant results have yet to be reconciled. A recent
study reported that GPR30 could decrease cAMP that was ele-
vated by heterologous ligands, such as forskolin, via the C-terminal
PDZ domain (85). This domain could bind membrane-activated
guanylate cyclases (MAGUKs), which act as adaptors for AKAP5
(PKA anchoring protein) that in turn decreased adenylate cyclase
activity. This would decrease the cAMP that is elevated by 17β-
E binding of the GPR30 and may serve to limit the time frame
of GPR30 signaling (85). Hence, both ERK and cAMP signaling
downstream of the GPR30 may be restricted to very short time
frames.
THE iGR AS THE mGR
Similar to the ERα being considered a possible mER, the intracel-
lular GR (iGR) that exists as a complex with heat-shock protein
90 (HSP90), p23, and a tetratricopeptide protein (86) in the
cytoplasm has been proposed as a candidate mGR (87). Stable
reduction of mGR levels in CD14+ monocytes using stably trans-
fected siRNA to iGRα suggested that both mGR and iGR were
derived from the same transcript (88). GR exists in two isoforms,
GRα and GRβ. GRβ, generated by alternative splicing, lacks the
last 50 amino acids of the GRα carboxy terminus, and instead pos-
sesses a unique 15 amino acid sequence at its C-terminus (89).
GRβ neither binds glucocorticoids nor has intrinsic transcrip-
tional activity, but has been implicated as a dominant negative
inhibitor of GRα activity through formation of a non-functional
heterodimer (90). Higher concentrations of GRβ relative to GRα,
therefore, result in decreased glucocorticoid sensitivity. However,
levels of GRβ protein in the brain are extremely low (89) and this
is not thought to be a regulator of GRα in the brain. The presence
of mGRα was detected at very low levels in human lymphocytes
and leukocytes using membrane-impermeable fluorescent lipo-
somes and GR-specific antibodies (91) such as M-20 (Figure 1).
Similar to the tethering of ERα to the plasma membrane, mGRα
has been associated with Cav-1 in MCF-7 cells (92). However,
while plasma membrane association of other steroid hormone
receptors, including ER, is dependent on palmitoylation, muta-
tion of the homologous sequence in GR did not affect membrane
localization (93), suggesting that other mechanisms must tether
mGR to the plasma membrane. In the brain, most of the rapid
effects of glucocorticoids have been confined to the hippocam-
pus and to the hypothalamus. Membrane glucocorticoid receptors
were first observed in the synaptic plasma membrane fractions
(SPM) of rat brain via [3H]-corticosterone binding assays (20).
Hypothalamic SPM had a higher binding capacity than hippocam-
pal or cortical SPM, which is in contrast to corticosterone binding
of the iGR, which is lower in the hypothalamus and much higher
in cerebral cortex and hippocampus (94). Synaptosomal fractions
from rat hippocampus contained plasma membrane-associated
GR (95) and GR immunoreactivity was observed at the plasma
membranes and vesicle membranes of the hypothalamus (96)
while in the CA1, GR was shown in the spine (97). Functionally,
JNK and p38 MAPK were activated within 10 min of glucocorti-
coid administration in primary hippocampal neurons (98). The
hypothalamo–pituitary–adrenal (HPA) axis is also subject to rapid
negative feedback at the level of the hypothalamus (99). Bath appli-
cation of glucocorticoids to rat hypothalamic slices caused a rapid
suppression of glutamate-mediated excitatory synaptic currents
onto CRH neurons that was decreased by a CB1 receptor antago-
nist (13). The release of endocannabinoids that bind to the CB1
receptor is dependent on corticosterone rapidly acting on the CRH
neuron and is dependent on Gαs-driven PKA activation in the
CRH neuron (100). However, the release of nitric oxide (NO)
that increased GABAergic inhibition (101) onto the CRH neuron
was dependent on Gβγ signaling (100). Hence, in the PVN, rapid
negative feedback by glucocorticoids on post-synaptic CRH neu-
rons is exerted by a combination of suppression of presynaptic
glutamatergic neurons and excitation of presynaptic GABAergic
neurons. The identity of the mGR that can signal via both Gαs and
Gβγ subunits in the CRH neuron remains unknown.
UNRESOLVED QUESTIONS: mER AND mGR
As is evident in the preceding sections, several questions about
the identity of the mER and mGR remain. Though the strongest
evidence exists for a post-translationally modified classical ER,
there are other viable candidates for the ER (102) based both on
evidence of proteins that interact with antibodies raised to the
classical ER or to the continued existence of non-genomic effects
in ERαKO and ERβKO mice (63). Different ER proteins might
be mERs in different tissues (14) or different proteins might be
mERs in the same tissue at different times to generate divergent
rapid signaling outcomes within the same cell or different tis-
sues that is congruent with incoming stimuli. It is also possible
that the time frame of non-genomic signaling might be differ-
ent when there are different mERs present – a GPCR such as
GPR30 may activate the ERK and PKA pathways very transiently
whereas ERα or ERβ at the membrane may be capable of more
sustained activation. Again, this would change the response of
the cell to stimuli, depending on the mER present. Second, if the
mER is the ERα, the mechanism by which only a small propor-
tion of the total ERα is targeted to the membrane is not known
and strengthens the idea that different pools of ERα may exist
within cells (30) with different functions. The rationale for the
variable amount of ERα at the membrane in some cells versus oth-
ers in cell lines is also unclear but could allow for 17β-E to employ
non-genomic versus genomic signaling to different extents in dif-
ferent cells, which maybe at different physiological states. Third,
apart from the difficulty in studying ERβ localization or inter-
action with other proteins due to the unavailability of a reliable
antibody (57), the localization of the ERα variants is also partic-
ularly understudied, but the predominance of the 52 kDa form
as opposed to the full-length 66 kDa form in the CNS (39, 52)
argues for an important role of these variants in estrogen signal-
ing in the brain, as opposed to other classical estrogen-responsive
tissues such as the uterus. The rapid actions of these different
ERα variants may also oppose each other in some cases (39). It is,
therefore, likely that the ratio of different ERs, including mERs
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expressed in each cell that determines the cellular response to
17β-E exposure. The significance of these spatially separated and
functionally opposing ER populations may be to modulate the
hypothalamic and hippocampal neuron response to estrogen and
prevent runaway signaling. Fourth, though the GPR30 has a role
to play in estrogen-mediated physiology, the acceptance of GPR30
as a mER has not been universal (103) with some investigators pre-
ferring to term it as a “collaborator” to the ERα, which is deemed
to be the primary mER that signals from the membrane (30). If
GPR30 or Gαq-coupled novel proteins are the mERs in some tis-
sues, it is also possible that they crosstalk with classical ERα or
ERβ, accounting in some studies for the ICI-mediated antagonism
of the effect. Though this cooperation between GPR30 and ERα
has been shown to have a proliferative effect on ovarian cancer
cells (104), a functional effect has not been demonstrated in the
hypothalamus. In the ventral hippocampus in male mice, Hart
et al. showed an injection of G-1 could increase the phosphory-
lation of an ERK-sensitive serine site on the ERα at position 118
within 30 min, suggesting that these two receptors could interact
with each in the CNS (105). Future studies on the colocaliza-
tion and the functional interaction between ERα and GPR30 in
the hypothalamus will prove useful in this regard. There are far
fewer studies on the mGR, when compared to the mER, and most
studies investigate the possibility of the mGR being equivalent
to the iGR. Surprisingly, the idea that different G-protein sub-
units, particularly that the Gβγ subunit can support signaling
from the unidentified mGR in the CRH neuron and from the
Gαq-coupled, STX-activated mER in the POMC neuron is also
seen with a traditional GPCR such as GPR30. Whether signaling
from both G-protein subunits is concomitant or if one signaling
pathway predominates, under certain physiological conditions, is
not known.
Lastly, the model generated by the existing literature is that the
mER or mGR is at the inner leaflet of the membrane, associated
with intrinsic membrane proteins or scaffolds such as caveolin.
However, surface biotinylation experiments imply that some part
of the mER or mGR is exposed to the extracellular mileu (18).
Though an abundance of hydrophobic amino acids in the ligand-
binding domain of the mER predicts that this domain might insert
into the plasma membrane (106), no study has demonstrated
this in the CNS. While recycling of this receptor from the mem-
brane is to be expected, the pathways (Rab-mediated or β-arrestin
mediated) are possibly cell-specific and are worthy of more atten-
tion since non-genomic signaling is possibly terminated during
internalization.
MORPHOLOGICAL AND BEHAVIORAL OUTPUTS IN THE CNS
DEPENDENT ON NON-GENOMIC SIGNALING BY ESTROGENS
AND GLUCOCORTICOIDS
Though kinase regulation and calcium flux has been shown to
occur rapidly when cells are exposed to the hormone in a number
of tissues and the idea of non-genomic signaling more accepted
than ever before, the relevance of non-genomic signaling for
behavior has remained murky. Here, we shall confine ourselves
to primarily hypothalamically driven behaviors or possible neural
correlates that are either rapidly induced by 17β-E or E2-BSA
or that may have a non-genomic component. Finally, we will
discuss the intersection of glucocorticoid rapid signaling in a
17β-E-mediated behavior.
SPINOGENESIS
Estrogen is critical in the display of female sex behavior in rodents
by acting on the hypothalamus; retrograde tract tracing using the
pseudorabies virus (PRV) injected into the lumbar muscles labeled
the lordosis circuit, in particular, the plexus of oxytocin fibers in
the vl-VMH (107). In the hypothalamus, estradiol benzoate (EB)
injections to ovariectomized rats increased spine density by 48%
in the vl-VMH as compared to oil injections (108). Surprisingly,
only 3% of PRV-labeled neurons were ERα+ and these were not the
neurons that showed an increase in spine density (109) upon EB
administration. These data argue that the increase in spine density
in the VMH may be only indirectly dependent on ERα signaling
or could be due to another ER while the longer time frames used
in the study do not allow us to conclude if there is a non-genomic
component. A candidate could be the GPR30 receptor, which is
expressed in the vl-VMH; the role of this receptor in spinogenesis
in the hypothalamus is not known. Rapid effects on spinogen-
esis and spine morphology following GR activation have been
observed in the hippocampus, but not in the hypothalamus. CA1
neurons from male rat hippocampal slices treated with dexam-
ethasone for 1 h demonstrated a translation-independent increase
in spine density, which was lost with co-application of dexametha-
sone with either the GR antagonist RU-486 or the NMDA receptor
blocker MK-801 (95). The proportion of mushroom-shaped and
thin-type spines was also increased following GR activation (95).
Does non-genomic signaling play a role in the increase in spine
density by estrogens or by glucorticoids? The mGluR1a antago-
nist, LY367385 in the ARH decreased phosphorylated cofilin levels
that are induced within an hour of EB injection and that are
required for actin reorganization and spinogenesis, suggesting that
at least some of the initial aspects of spinogenesis are mediated via
non-genomic signaling from the ERα-mGluR1a complex at the
membrane (110). Though EB can increase filopodial spines in
the ARH within 4 h of treatment, mushroom shaped, more stable
spines require time frames in excess of 20 h and parallels the time
frames required for the full display of lordosis behavior, suggest-
ing that rapid non-genomic signaling is insufficient for formation
of stable spines (110). Stabilization of the PSD-95 protein, a scaf-
folding protein enriched in mushroom-shaped dendritic spines,
was dependent on pAkt and also required 48 h of 17β-E treat-
ment in differentiated NG-108 cells (111). Another model for the
increase in 17β-E-mediated increase in spine density in the hypo-
thalamus is that 17β-E stimulates PI3K activation pre-synaptically,
inducing glutamate release, followed by NMDA receptor activation
and ERK signaling post-synaptically, with a subsequent increase
in spinophilin protein that was correlated with an increase in sta-
ble dendritic spines (112) on the post-synaptic neuron. Both ERK
and PI3K signaling are implicated in the increase in spine density,
though the formation of mature mushroom spines also appears
to require transcription (113). Though there are no reports of
glucocorticoid-mediated regulation of spine density in the hypo-
thalamus, suppression of PKA, PKC, MAPK, or PI3K signaling
completely blocked GR-mediated spinogenesis in CA1 neurons,
suggesting that GR signals through convergent kinase pathways
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to increase actin polymerization, which would allow for spine
changes (114). In CA1 neurons, treatment with the synthetic
glucocorticoid dexamethasone increased p-cofilin levels within
30 min, similar to the rapid induction seen in the ARH by EB (97).
Consistent with the idea that 17β-E-mediated spinogenesis in
the VMH has a functional consequence, cytochalasin D, an actin
polymerization inhibitor, blocked the formation of spines in the
ARH and reduced lordosis (110) though the relevance of such
spinogenesis to sex behavior in rodents (see Sex Behavior or Lordo-
sis in Females) is unknown. The consequences of spine disruption
for other behaviors such as aggressive behavior or male sex behav-
ior (see Male Sex Behavior) are also unknown. Though most of
the studies have shown effects on spine density or morphology in
longer time frames that do not allow one to parse non-genomic
actions from transcription, spine density on the apical dendrite in
the stratum radiatum and in the stratum lacunosum moleculare of
the CA1 neuron was increased within 40 min by the ERα selective
agonist, propyl pyrazole triol (PPT); however, these were at high
doses that were not correlated with doses of PPT that led to an
improvement in social memory within 40 min of administration
(115). In mature rat cortical neurons, 17β-E rapidly increased ERK
and p21-activated kinase to increase dendritic spine density (116)
within 30 min. Though this suggests that non-genomic signaling
may be sufficient for an increase in spine density at least in the
hippocampus and cortex, this has to be confirmed with experi-
ments that utilize a transcription inhibitor. A similar rapid effect
of estrogen on spine density in the hypothalamus has not been
demonstrated.
SEX BEHAVIOR OR LORDOSIS IN FEMALES
Lordosis in rodents is a 17β-E-driven behavior where integration
of sensory information within the limbic-hypothalamic circuit
culminates in VMH projections onto neurons of the periaque-
ductal gray (PAG) and spinal cord motor neurons, resulting in
the classical lordosis posture (16). A series of elegant experiments
from the laboratory of Micevych delineated a microcircuit con-
sisting of neuronal afferents from the ARH to the mPOA (113).
In this circuit, the initial membrane-initiated signaling by 17β-E
in the ARH neurons increased PKCθ (117) and released neu-
ropeptide Y that activates β-endorphin expressing ARH neurons
that project into the mPOA (118). In the mPOA, β-endorphin
released from the ARH caused the internalization of µ-opioid
receptors (MOR) within 30 min of E2-BSA (119) administra-
tion into the ARH, suggesting that this is a membrane-initiated
non-transcriptional event. This transient inhibition of lordosis
initiated by MOR internalization is removed 30 h later by prog-
esterone (120). A number of different receptors, including ERα
and mGluR1a, play a role in this membrane-initiated signaling
to influence lordosis behavior. Not only does ERα and mGluR1a
colocalize in about 23% of ERα-expressing neurons but deletion
of ERα also blocked MOR internalization in the mPOA (121) and
abolishes lordosis (122). Blocking of MOR internalization with
application of an mGluR1 antagonist or Cav-1 siRNA into the
ARH also, in turn, reduced lordosis (119, 123). Though this sug-
gests that ERα and mGluR1 signal together as in the hippocampus
(124), the selective mER agonist, STX in the ARH also induced
MOR internalization and lordosis (125), an effect blocked by the
mGluR1a antagonist. This suggests that in the ARH, both ERα
and the Gαq-mER may couple to mGluR1a and facilitate lordosis,
though the mechanisms by which this occurs are unclear. Apart
from these receptors, the localization of the GPR30 in the hypo-
thalamus (126) and the ability of G-1, an agonist at the GPR30 to
facilitate lordosis in female ovariectoimized mice (127) argues that
GPR30 signaling is also important, at least in mice. It is unknown
if the ERα, the Gαq-mER, and the GPR30 interact or signal to each
other or represent independent parallel signaling pathways that
drive lordosis in estrogen primed ovariectomized female rodents,
though any model must take into account the necessity of ERα in
the VMH for lordosis.
Since Kow et al. demonstrated that E2-BSA alone in the VMH
does not induce lordosis (128), we can presume that non-genomic
signaling is insufficient but may potentiate or prime lordosis
that is in itself dependent on nuclear transcription (129) via
a coupled signaling pathway (130). Consistent with this idea, a
mouse that possesses an ERα that cannot bind an ERE (ERα−/AA)
(131) did not display lordosis behavior (132), demonstrating the
importance of 17β-E-bound ERα transcriptional action at an ERE
for lordosis. Also, combined E2-BSA and 17β-E administrations
into the VMH increase progesterone receptor (PR) protein levels
higher than either hormone alone (133), demonstrating potentia-
tion of transcription by a membrane-limited estrogen conjugate.
The reduction of ERα in the VMH using adenovirus-associated
shRNA viral vectors that abolished lordosis behavior (29) shows
the absolute requirement for the ERα, which could be due to its
participation both as a mER and as a nuclear transcription factor
in the VMH. An additional role could be the signaling initiated
by ERα acting as a mER in the ARH but as a transcription factor
that upregulates the PR in the VMH (134), both processes that are
required for lordosis. In this scenario, membrane-initiated signal-
ing in the ARH results in transient inhibition of lordosis so that
17β-E can transcriptionally activate genes such as the PR in the
VMH that are important for the full display of lordosis that occurs
30 h later (113).
MALE SEX BEHAVIOR
In males, 17β-E given intraperitoneally at high concentrations to
castrated adult rats increased some aspects of male sex behav-
ior, i.e., genital sniffs and mounting within 15 min, a time frame
commensurate with non-genomic actions (135). However, since
protein synthesis inhibitors (136) and the presence of the ERE-
binding mutant, the ERα−/AA mouse abolished male sex behavior
(131), it is reasonable to conclude that male sex behavior, similar
to female sex behavior, has a non-genomic component that is not
sufficient for the full display of the behavior. Though most of the
studies investigate the role of testosterone in males (137, 138),
testosterone can be converted to 17β-E by aromatase (139). In the
castrated and testosterone supplemented quail that was treated
with the aromatase inhibitor, vorozole, administration of 17β-E or
E2-BSA intracerebroventricularly (icv) increased appetitive sexual
behavior but not the final consummatory aspects of sexual behav-
ior within 15 min (140). This appetitive sexual behavior was also
blocked by vorozole, administered icv 15 min before behavioral
testing (140). This implies that neuroestrogens that are rapidly
generated in response to stimuli such as the sight of a female signal
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rapidly to initiate appetitive sexual behavior. Though ICI 182,780
antagonized the increase in appetitive sexual behavior seen rapidly
with 17β-E administration (140), the exact mER that mediates
the rapid regulation of sex behavior or aromatase in the quail or
the mouse is unknown. In the male mouse, consistent with the
interpretation that arises from the data in the quail, 17β-E admin-
istered to aromatase knockout male mice reversed the lack of sex
behavior while vorozole decreased sex behavior in C57BL/6 mice
within 15 min of administration (141). Stimuli-dependent rapid
regulation of aromatase could represent a mechanism to locally
elevate neuroestrogens, which then increase sex behavior in male
quail or in the male rodent. However, contrary to this expecta-
tion, aromatase activity decreased rapidly when male quail were
exposed to female stimuli but neuroestrogen concentrations itself
increased in the mPOA (142), a nuclei important for male sex
behavior. However, it is important to note that the acute action of
17β-E on appetitive sexual behavior in the male quail was always
preceded by initial copulation with a receptive female to establish
this learned response, wherein the sight of the same female would
initiate appetitive sexual behavior (143). In this case, it is possible
that prior sexual experience may initiate transcriptional signaling
by 17β-E, which in turn primes rapid non-genomic signaling to
achieve greater efficiency in subsequent sexual interactions and
optimize reproduction; this remains to be tested. Similar to female
sex behavior, the non-genomic component in male sex behavior is
important for the initial approach and mounting aspects of male
sex behavior.
AGGRESSION IN MALES
Castration in male rodents removes both testosterone and estro-
gens and results in loss of aggression in response to territorial
intrusion (144, 145). The importance of estrogen in male aggres-
sive behavior is shown by the deletion of aromatase, which abol-
ished aggression by male mice in a resident-intruder paradigm,
though this is possibly also due to organizational defects since
17β-E reinstated aggression only when administered before post-
natal day 7 (146). In CD-1 outbred male mice, ERα concentrations
in several areas of the circuit involved in aggression such as the
bed nucleus of the stria terminalis (BNST), the lateral septum
(LS), and the anterior hypothalamus (AH) was higher in more
aggressive mice (147). Reduction of ERα in the VMH by aden-
ovirus mediated transfer of siRNA to ERα abolished aggressive
behavior in male mice, demonstrating that ERα expression in the
VMH is necessary for aggression in adult male mice (29), just as it
was important for sex behavior in male mice. In California, beach
mice that were castrated and supplemented with testosterone and
an aromatase inhibitor so that they possessed testosterone but
not estrogen, aggression increased rapidly within 15 min of injec-
tion with cyclodextrin-conjugated 17β-E (148). This suggests that
testosterone alone was not sufficient to elicit aggressive behavior
in a resident-intruder paradigm and that 17β-E is necessary to
activate aggression. The time frame and the inability of cyclohex-
imide (149) to decrease this aggression in the beach mouse argue
that 17β-E acts non-genomically, though most studies on aggres-
sion, with the exception of those cited in this paragraph, in the rat
and mouse have used time frames that do not allow us to parse a
non-genomic effect from a genomic/coupled signaling effect.
What is the source of 17β-E? In rodents, aromatase is expressed
in axon terminals (150–152) particularly in the hypothalamus
(153) and brain 17β-E concentrations in the male rat are equal
to or higher (~8 nM) than in the plasma (154). Hence, 17β-E
generated at the synapse has been envisioned to function as a
neuromodulator in short time frames (155), in line with the data
in male birds where neuroestrogens generated at axon terminals
are important in learning in songbirds (156) and in sex behavior
in the quail (157, 158). In the castrated male rat, EB synergized
with dihydrotestosterone (DHT) to increase aromatase activity
(159). In addition, 17β-E can transcriptionally induce the aro-
matase gene via ERα-c-jun complex binding to AP-1 elements in
the brain-specific promoter of aromatase (160). Therefore, sim-
ilar to spinogenesis, the regulation of aromatase by 17β-E itself
may represent another correlate where both rapid, non-genomic
and slower, transcriptional mechanisms converge. The areas of the
brain wherein this may occur in the rodent are not clear and are
being investigated in our laboratory.
Though 17β-E can rapidly increase aggression by modulating
neurotransmitter release [(145) and references therein], it may
also do via regulating the HPA axis. In the white-crowned spar-
row, neither brain 17β-E concentrations nor aromatase activity
in nuclei involved in aggression were correlated with aggressive
behavior (161) though corticosterone did increase rapidly. What is
the link between glucocorticoids and aggression? Though aggres-
sion itself is stressful and leads to secretion of glucocorticoids,
dominance in an aggressive encounter typically leads to lowering
of the corticosterone level (162). However, pre-fight corticosterone
levels have been shown to be associated with aggressiveness in fish
and acute treatment with adrenocorticotrophic hormone (ACTH)
increased fighting behavior in male mice (163) while acute treat-
ment with corticosterone 2 min before an encounter increased
aggressiveness in male rats (164) and risk assessment in the open
field and elevated plus maze tests (165). Supporting the idea that
corticosterone is important in regulation the onset of aggressive
behavior, acute treatment with GR antagonists (166, 167) or pre-
vention of glucocorticoid synthesis (164) prevented aggression
when presented with social challenge. Since acute central appli-
cation of corticosterone increased aggression within 7 min and
protein synthesis inhibitors did not decrease it, non-genomic sig-
naling by glucocorticoids in the CNS is most likely required to
increase aggression (164). Consistent with this idea, acute cor-
ticosterone injection also decreased the magnitude of electrical
stimulation to the hypothalamus required to elicit attack (168).
In addition, corticosterone administration to rats in established
colonies did not change aggression, demonstrating that glucocor-
ticoids promote aggression only in ethologically relevant situations
such as territorial intrusion (169). However, chronic elevated lev-
els of glucocorticoids, such as seen in stressed or socially defeated
animals decrease aggression and increased submissiveness in ham-
sters (170, 171), mice (172), and rats (173, 174). This is thought to
be due to genomic signaling by glucocorticoids though the mol-
ecular mechanisms by which glucocorticoids facilitate or inhibit
aggression are unclear (175).
Gonadal status can modify the actions of glucocorticoids on
the hypothalamus or can regulate corticosterone levels itself. For
example, gonadal steroids can modify glucocorticoid-mediated
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FIGURE 2 | Hypothetical model in the rodent for the rapid and
sustained increase in aggression that is seen when an intruder
enters a resident’s home-cage. On visual and/or olfactory cues, 17β-E
in the brain may increase corticosterone via an unknown mechanism.
This increase in corticosterone may rapidly and non-genomically increase
aggressive behavior. The mechanism by which corticosterone does so is
not known but may involve the regulation of aromatase and could be GR
mediated. It is not known if 17β-E’s regulation of aggressive behavior is
solely via corticosterone increase or these are two parallel pathways,
which require ERα, as shown in the figure. Elevated corticosterone levels
can increase transcription from the brain-specific aromatase promoter,
which in turn increases neuroestrogens. This may contribute to shorter
latencies of attack in successive bouts. The interaction of estrogen and
corticosterone ensures that the resident rodent is aggressive only in the
presence of a relevant external cue, i.e., intruder and a relevant internal
cue, i.e., sufficient 17β-E.
negative feedback on CRH. 17β-E chronically administered to
gonadectomized and adrenalectomized female rats treated with
high doses of corticosterone increased CRH mRNA levels, thus
counteracting negative feedback, while DHT treatment to male
rats had an opposing effect and caused a further decrease in
CRH levels (176). In female ovariectomized rats, icv, but not
systemic, 17β-E injection increased corticosterone rapidly within
30 min, an effect mimicked with the ERα selective agonist, PPT,
injected into the PVN (177). In gonadectomized male rats, CRH
mRNA was higher when they were treated with EB but lower
when treated with DHT, implying that estrogens can regulate the
HPA axis in males also (178). A number of mechanisms may be
involved in the rapid increase of aggression by glucocorticoids in
response to social challenge, including the regulation of dopamine
(179, 180) and serotonin (181, 182) neurotransmission. Here, we
will focus on one such mechanism that is responsive to both
estrogens and glucocorticoids in the hypothalamus, namely, the
regulation of aromatase. Acute stressors, which increase gluco-
corticoids, increased neuroestrogen concentrations in the PVN
and aromatase mRNA in the PVN within an hour in female rats,
suggesting that corticosteroid release may also increase neuroe-
strogen in the hypothalamus (183). Similarly, in male quail, rapid
increases in aromatase activity also occurred on restraint stress
in the mPOA (184), demonstrating that corticosterone can affect
aromatase using a non-genomic signaling mechanism that is yet
unknown, in both birds and rodents. Furthermore, aromatase pro-
tein levels are increased in response to glucocorticoid treatment in
a hypothalamic cell line via a transcriptional mechanism (185),
leading to a possible increase in the amount of aromatase that
may increase the efficiency of winning future bouts. These data
demonstrate that 17β-E in the brain can increase plasma corti-
costerone, which in turn can increase aromatase activity and/or
transcription in the hypothalamus leading to a positive feedback
circuit that may be active under physiologically relevant stressful
contexts such territorial intrusion. The relevance of this pathway
ER
ER ER
ERE
E
PKB/Ca+2/
ERK
E
cre
C-Fosc
PKA
P? P
FIGURE 3 | Priming of transcription within neurons by non-genomic
signaling. Non-genomic signaling, initiated at the plasma membrane by an
unknown mER can activate ERK signaling, which in turn may cause
phosphorylation of the ERα and increased transcription from promoters
than contain EREs (130). Alternatively, ERK signaling may also lead via
unknown mechanisms to increased transcription from the c-Fos promoter
(190) while PKA signaling generated by the mER may lead to increased
transcription from promoters that have a cAMP response element (CRE)
enhancer (189).
(Figure 2) to aggression is under active investigation in our lab-
oratory, with the idea that glucocorticoid control of aggressive
behavior is dependent on neuroestrogen concentrations in the
brain.
FUNCTIONS OF NON-GENOMIC SIGNALING
One function of non-genomic signaling within a cell could be to
provide cells with another pathway by which they can respond
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differently to the same endogenous ligand. For example, acute
signaling by glucocorticoids increases aggression in an etholog-
ically relevant context but chronic signaling by glucocorticoids
increases submission (186). A parallel is seen with the regu-
lation of the CRH neuron by acute or chronic glucocorticoid
exposure via the regulation of synaptic inputs in the opposite
direction. In the acute phase, rapid signaling by glucocorticoids
increases negative feedback on the CRH neuron decreasing the
firing of the neuron (187), while chronic exposure to glucocorti-
coids decreases negative feedback on the CRH and increases CRH
mRNA, increasing HPA axis reactivity (188). A second function
of membrane-initiated signaling might be to prime nuclear tran-
scription via the phosphorylation of ERα, seen in a neuroblastoma
cell line (130) (Figure 3), leading to greater transcription from
genes with EREs in their promoters. In some cases, rapid signal-
ing could also activate genes that do not have classical EREs in
their promoters. For example, PKA signaling induced by 17β-E
in the SK-N-SH neuronal cell line was required to induce the
neurotensin/neuromedin gene (189), while E2-BSA in this cell
line activated a reporter gene driven by a c-Fos promoter in an
ERK-dependent manner (190). The idea that non-genomic sig-
naling might prime later outputs such as behavior is also evident
from the studies on sex behavior in female and male rodents.
Apart from the potentiation of transcription by rapid signaling,
non-genomic signaling could also decrease transcription if the
decrease in transcription is ultimately important in leading to
an optimal cellular response. For example, the increase in PI3K
and MAPK activation that occurs within 30 min via ERα in the
mHypoE-38 hypothalamic cell line is required for the long-term
repression of neuropeptide Y by 17β-E (191). Third, non-genomic
signaling via one pathway could also synergize with rapid signaling
pathways initiated by other ligands. For instance, 17β-E-induced
increases in calcium in POMC neurons augmented the activation
of the calcium-sensitive TRPC channels (192) already upregu-
lated by leptin (65). Additionally, 17β-E also transcriptionally
induced PI3K p85 subunit in the hypothalamus (193, 194) and this
combined with the non-genomic signaling-mediated increase in
calcium potentiates the PI3K and calcium-mediated TRPC chan-
nel opening activated by leptin (70). In this case, 17β-E utilized
both non-genomic, i.e., calcium increase and genomic signaling,
i.e., PI3K transcriptional upregulation to synergize with the rapid
signaling initiated by the leptin receptor to converge onto neuronal
depolarization. Fourth, non-genomic signaling pathways may also
synergize with a parallel, independent transcriptional pathway, in
response to the same ligand. The rapid action of glucocorticoids
in decreasing glutamatergic inputs to the CRH neuron combined
with slower transcriptional downregulation of the CRH and vaso-
pressin gene are dual pathways that achieve negative feedback
Spinogenesis
Estrogen: 
1. Akt activation à glutamate release à NMDAR 
activation à ERK activation à increased spinophilin
2. mGluR1-dependent increased cofilin phosphorylation
Glucocorticoid:
1. NMDAR-mediated increased cofilin phosphorylation
2. Spinogenesis dependent on MAPK, PI3K, PKA, PKC 
signaling
Male Territorial Aggression
Estrogen: 
Rapid estrogen signaling through ERα
required
Glucocorticoid:
Rapid glucocorticoid signaling required
Corticosterone increases aggressive behavior
Synergism with Other Rapid Signaling Pathways
Estrogen: 
Increased Ca++ à increased TRPC channel activation by leptin signaling
Glucocorticoid:
Neuroestrogen stimulation may increase ER activation
Aromatase
Increased aromatase mRNA
Increased aromatase activity
Increased neuroestrogen
Neuronal Inhibition
1. Gαs activation à PKA activity à endocannabinoid 
release à CB1R activation à suppression of 
glutamate-mediated excitatory synaptic currents
2. Gβγ activation à NO production à increased 
GABAergic inhibition
** net effect of negative feedback on CRH neurons
Neuronal Excitability
Gαq activation à PLC activity & Ca
++
release à PKC & PKA activation à
increased GIRK phosphorylation à
increased MOR uncoupling à decreased 
hyperpolarization
**net effect is increased excitability
Lordosis
Increased PKCθ & NPY à activation of β-
endorphin expressing neurons à POMC 
neurons internalize MOR à lordosis
**ERα-mGluR1 dependent
G-1 sufficient, therefore may involve GPR30 
or ERα-36
Priming for Genomic 
Effects
Phosphorylation of ERα at S118 
may modulate later genomic 
effects of estrogen
Male Appetitive Sex Behavior
Neuroestrogen dependent
mGR
mER
FIGURE 4 | Functions of non-genomic signaling initiated by the
mER or the mGR in the CNS. Both mER and mGR contribute to the
regulation of male territorial aggression and spinogenesis in neurons,
as well as synergizing with other rapid signaling pathways. In the
pre-opiomelanocortin (POMC) neuron shown on the left, non-genomic
signaling by the mER increases neuronal excitability while rapid
negative feedback by the mGR in corticotropin releasing hormone
(CRH) neurons decreases neuronal excitability (shown on the right). In
addition, the mER plays a role in male sexual behavior and may interact
with GPR30 regulates lordosis behavior in female rodents.
Glucocorticoids via the mGR also increase neuroestrogen
concentrations, via aromatase activity and the increase in aromatase
protein, thus providing a route by which the actions of estrogens and
glucocorticoids can converge in the brain.
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Table 2 | Receptors that are activated or inhibited by the natural
estrogen 17β-estradiol, the natural glucocorticoid, corticosterone, a
membrane-limited estrogen conjugate (E2-BSA) or glucocorticoid-
conjugate (Dex-BSA), or selective agonists or antagonists.
Hormone/drug Receptor activation Receptor
antagonism
Reference
17β-estradiol All ERs None
E2-BSA All mERs None
Propyl pyrazole
triol (PPT)
ERα; 410-fold
selectivity over ERβ.
Also binds GPR30
None reported (199)
R,R(THC) ERα ERβ (200)
Diarylpropionitrile
(DPN)
ERβ; 70-fold
selectivity over ERα
None reported (201)
ICI 182,780 GPR30 ERα/ERβ (202)
G-1 GPR30 and ERα-36 None reported (60)
G-15 ERα or ERβ; activates
ERE
GPR30 (203)
G-36 None reported GPR30 (203)
Corticosterone All GRs None reported (204)
Mineralocorticoid
receptor
Dexamethasone All GRs None reported (204)
MR (30% of affinity to
GR)
Dex-BSA All mGRs None reported
RU-486
(mifepristone)
None reported GR,
progesterone
receptor
(205)
As can be seen, several selective agonists or antagonists show cross-reactivity
to other receptors for estrogens and to other receptors for mineralocorticoids and
progestins, in the case of the glucorticoids. Hence, results obtained using these
compounds must be carefully interpreted.
MR, mineralocorticoid receptor.
regulation in the PVN (19). Glucocorticoid-mediated rapid reg-
ulation of aromatase combined with the slower transcriptional
increase or aromatase mRNA and protein is yet another exam-
ple where both modes would finally increase neuroestrogens in
the hypothalamus. Lastly, non-genomic signaling in one cell type
may also synergize with genomic signaling in another cell type
to converge onto behavioral outputs. This is demonstrated by the
ability of 17β-E to elicit a rapid calcium increase in hypothalamic
astrocytes that is required for the increased synthesis of neuroprog-
esterone (195). This release of progesterone that binds to the PR
that is transcriptionally induced by the liganded ERα in hypothal-
amic neurons is required for lordosis behavior in rodents (195).
Some of these functions of non-genomic signaling are shown in
Figure 4.
FUTURE DIRECTIONS
Understanding the many facets of non-genomic signaling would
also spotlight the role and source of the ligand. The idea that local
estrogen synthesis in the brain, i.e., neuroestrogens is important
in transducing environmental stimuli to behavior is fairly recent
and has mostly been explored in birds (155, 156, 196). In addition,
this would bring into focus the role of estrogens in males; tra-
ditionally, classical female-typical behaviors such as lordosis have
received far more attention in the estrogen field. Second, many of
the studies described above were done in rats whereas there are
hints that there may be subtle differences in the mouse. For exam-
ple, though there is very little GPR30 protein reported in the rat
amygdala (76), there is high expression of GPR30 in the mouse
basolateral amygdala and intra-amygdalar injection of G-1 atten-
uates behaviors that denote anxiety in the mouse (197). Similarly,
though G-1 failed to regulate sex behavior in the female rat (198),
it could do so in the female mouse (127). Though studies on rapid
non-genomic signaling have become more mainstream, a num-
ber of mechanistic aspects of non-genomic signaling and coupled
signaling remain unknown including the temporal nature of the
shift from non-genomic signaling to genomic signaling. The role
of the ERα variants and GR variants in any of these hypothalam-
ically driven behaviors or in spinogenesis is unclear, with almost
no studies on the subject. In this regard, it is worth nothing that
studies using agonists or antagonists should be careful to verify if
the effects are specific – for example, some of the G-1 mediated
effects could be via ERα-36 and some of the ICI-mediated effects
could be via GPR30 (Table 2).
Complementary studies using deletions of the genes in animals
or preferably using site-specific or temporally specific deletion
would prove useful to establish specificity. The detailed molecular
pathways by which 17β-E regulates spinogenesis or behaviors in
the VMH are also not well worked out, though there has been con-
siderable progress in the last decade on the receptors that might be
involved. Lastly, understanding non-genomic signaling is possibly
a mechanism to convey information about external physiologically
relevant stimuli rapidly to the animal to generate both acute and
chronic outcomes.
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